Hydromorphone transdermal - Altea Therapeutics

Drug Profile

Hydromorphone transdermal - Altea Therapeutics

Alternative Names: AT-1022; AT-2022

Latest Information Update: 15 Nov 2012

Price : $50

At a glance

  • Originator Altea Therapeutics
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 12 Nov 2012 Nitto Denko acquires all assets of Altea Therapeutics
  • 09 Dec 2011 Discontinued - Phase-II for Pain in USA (Transdermal)
  • 29 Aug 2005 This product is still in active development - BIO-2005 Annual International Convention (BIO-2005)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top